The company has two products candidates in late stage clinical development, which include Veronate and Aurexis.
Veronate, which is in phase III clinical development, is being developed to prevent hospital-associated infections in very low birth weight infants.
Aurexis is being developed to treat, in combination with antibiotics, Staphylococcus aureus infections in hospitalized patients.
Aurexis completed a phase II clinical trial in May 2005.
In addition, the company has three preclinical product candidates under development, including Enterococcus monoclonal antibody for the treatment of enterococcus infections; Candida monoclonal antibody for the treatment of candida infections; and Staphylococcal vaccines for active immunity against Staphylococcal infections.
Inhibitex was co-founded by Joseph M.
Patti and Magnus Hook.
It was incorporated in 1994 and is based in Alpharetta, Georgia.
